Literature DB >> 9749831

Is there a "non-MAO" macromolecular target for L-deprenyl?: Studies on MAOB mutant mice.

J Ekblom1, L Oreland, K Chen, J C Shih.   

Abstract

Several irreversible inhibitors of monoamine oxidase B, can promote survival of damaged neurons in several animal models of cerebral injury. Today it is evident that this effect is not a consequence of monoamine inhibition. Instead it has been proposed that L-deprenyl may act via an unrelated non-monoamine oxidase type- of binding site. In the present study we have investigated if brain tissue from MAOB knockout mice contain such "non-MAO" binding sites for radiolabelled deprenyl. Interestingly, no binding of L-deprenyl was observed indicating that the mother compound does not act directly via a macromolecular target. This is enticing since several alternative mechanisms of action have been proposed in the literature.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9749831     DOI: 10.1016/s0024-3205(98)00370-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  R-deprenyl: pharmacological spectrum of its activity.

Authors:  K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

2.  Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.

Authors:  Keiko Inaba-Hasegawa; Yukihiro Akao; Wakako Maruyama; Makoto Naoi
Journal:  J Neural Transm (Vienna)       Date:  2011-11-08       Impact factor: 3.575

Review 3.  Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2017-12-26       Impact factor: 3.575

4.  (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.

Authors:  J Knoll; F Yoneda; B Knoll; H Ohde; I Miklya
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

5.  Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.

Authors:  Keiko Inaba-Hasegawa; Masayo Shamoto-Nagai; Wakako Maruyama; Makoto Naoi
Journal:  J Neural Transm (Vienna)       Date:  2017-06-02       Impact factor: 3.575

Review 6.  Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.

Authors:  Makoto Naoi; Peter Riederer; Wakako Maruyama
Journal:  J Neural Transm (Vienna)       Date:  2015-01-22       Impact factor: 3.575

Review 7.  Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.